EU H2020 Project "EPIORGABOLISM (Diabetic nephropathy modelling in hESC-derived 3D kidney organoids)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/220331/index.html
-1	/open-fp7/projects/186234/index.html
-2	/open-h2020/projects/214202/index.html

EPIORGABOLISM project word cloud

Explore the words cloud of the EPIORGABOLISM project. It provides you a very rough idea of what is the project "EPIORGABOLISM" about.

genes occurring lack evidences patients drug fatty alterations montserrat acid date therapeutic reprograming human crispr acting aberrant progression differentiation recapitulate proximal functional preclinical fibrosis models nephropathy oxidation dn kptcs impediments therapy mainly signature molecular enzymes model epigenome therapies drugs links chemistry stop treatment engineered tissue pathology elucidate glycaemic stage blood diabetes epithelial ing dna vivo dr structural pressure discovery metabolic gained regeneration genetic architecture promoters epigenetic background kidney expertise metabolism tubular promoted esrd good status validated cas9 embryonic mimic somatic vitro hypothesize organoids regulators physiological cell serve methylation stem enhancers disease stages reprogramming cells encoding renal tool diabetic hesc

Project "EPIORGABOLISM" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA Organization address address: CARRER BALDIRI REIXAC PLANTA 2A 10-12 city: BARCELONA postcode: 8028 website: http://www.ibecbarcelona.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	158˙121 €
EC max contribution	158˙121 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2017
Funding Scheme	MSCA-IF-EF-RI
Starting year	2019
Duration (year-month-day)	from 2019-04-18 to 2021-08-14

#	participants	country	role	EC contrib. [€]
1	FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA	ES (BARCELONA)	coordinator	158˙121.00

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

ES (BARCELONA)

coordinator

158˙121.00

Project objective

Diabetic Nephropathy is the leading cause of end-stage renal disease (ESRD). To date, treatment of DN is mainly based on drugs acting on glycaemic and blood pressure control, as there is no validated therapy able to stop the progression towards renal failure. One of the main impediments for developing new therapies for DN has been the lack of a good preclinical model which can recapitulate important functional, structural, and molecular features of advanced human diabetic kidney disease. Here, we aim to develop a DN modelling using human Embryonic Stem Cell (hESC) derived kidney organoids which can recapitulate the in vivo architecture, functionality, and genetic signature of DN. Due to the increasing evidences that links aberrant DNA methylation with kidney fibrosis and metabolic reprograming in DN, we hypothesize that early DN progression is promoted by the metabolic alterations occurring in diabetic patients, resulting in the epigenetic reprogramming of kidney proximal tubular epithelial cells (KPTCs). Based in my background in the fields of metabolism and diabetes, together with the expertise of Dr. Montserrat in the field of somatic reprograming, DN and tissue regeneration/differentiation, this proposal seeks to:1) Elucidate the methylation status of the promoters/enhancers of genes encoding enzymes and regulators of fibrosis and fatty acid oxidation in proximal tubular cells obtained from diabetic patients at different stages of DN progression 2) Establish two in vitro models using hESC-derived kidney organoids; an engineered DN in vitro model, using CRISPR Cas9 to mimic the epigenome signature of DN patients and a physiological DN in vitro model which mimic the diabetic physiological chemistry. The information gained from this DN modelling will offer improved insight into disease pathology and progression. Moreover, it may also serve as a tool for drug discovery to identify therapeutic targets for DN.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIORGABOLISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIORGABOLISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)